IO Biotech posts Q2 2025 results update

IO Biotech, Inc. filed a current report to note that it has released its financial results for the fiscal quarter ended June 30, 2025.

Rhea-AI Filing Summary

IO Biotech, Inc. filed a current report to note that it has released its financial results for the fiscal quarter ended June 30, 2025. The company issued a press release on August 14, 2025 sharing quarterly results and providing an update on its operations for the same period.

The press release is included as Exhibit 99.1 and is being furnished rather than filed, which means it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IO Biotech, Inc. (IOBT) disclose in this 8-K?

The company disclosed that it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and provided an update on its operations for that period.

Which period do the IO Biotech (IOBT) results cover in this report?

The financial results and operational update relate to the fiscal quarter ended June 30, 2025.

How did IO Biotech (IOBT) present the earnings press release to the SEC?

The earnings press release is furnished as Exhibit 99.1 to the report, rather than being formally filed under Section 18 of the Exchange Act.

Does the IO Biotech (IOBT) earnings press release become part of other SEC filings?

It is not incorporated by reference into other Exchange Act or Securities Act filings unless a future filing expressly includes it by specific reference.

Who signed this IO Biotech (IOBT) 8-K report?

The report was signed on behalf of IO Biotech, Inc. by Mai-Britt Zocca, Ph.D., the company’s Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 04:31 PM EDT Learn about SEC filing dates

false 0001865494 0001865494 2025-08-14 2025-08-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 14, 2025

IO BIOTECH, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware		001-41008		87-0909276
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Ole Maaløes Vej 3

DK-2200 Copenhagen N

Denmark

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: +45 7070 2980

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		IOBT		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On August 14, 2025, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of the Company dated August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IO BIOTECH, INC.
Date: August 14, 2025				By:		/s/ Mai-Britt Zocca
				Name:		Mai-Britt Zocca, Ph.D.
				Title:		Chief Executive Officer